Skip to content
    Guidelines & Consensus

    ESTRO-EORTC Oligometastatic Classification in Ovarian Cancer: Key Implementation Barriers

    Macchia et alThe Lancet Oncology

    The oligometastatic disease classification framework, developed through the European Society for Radiotherapy and Oncology (ESTRO) and European Organisation for Research and Treatment of Cancer (EORTC) OligoCare project, aims to standardize prognostic stratification and clinical trial design across solid tumors. However, applying this system to ovarian cancer presents distinct challenges due to disease-specific features: early, diffuse peritoneal dissemination and the technical difficulty of enumerating lesions when peritoneal deposits lack discrete measurable boundaries.

    Key Takeaways

    • Early diffuse peritoneal dissemination and the challenge of enumerating non-discrete peritoneal deposits impede the clinical application of the ESTRO-EORTC OligoCare classification framework in ovarian cancer.
    Read the original sourceThe Lancet Oncology